相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Lukas Perkhofer et al.
GUT (2021)
Temporal modulation of the NF-κB ReIA network in response to different types of DNA damage
Amy E. Campbell et al.
BIOCHEMICAL JOURNAL (2021)
The Hammer and the Dance of Cell Cycle Control
Andreas Panagopoulos et al.
TRENDS IN BIOCHEMICAL SCIENCES (2021)
Treatment landscape of metastatic pancreatic cancer
Sara De Dosso et al.
CANCER TREATMENT REVIEWS (2021)
Surgical Treatment of Pancreatic Ductal Adenocarcinoma
Kongyuan Wei et al.
CANCERS (2021)
The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
Marwa Elsayed et al.
BIOMEDICINES (2021)
Hypertranscription and replication stress in cancer
Akhil Bowry et al.
TRENDS IN CANCER (2021)
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
Alexander Biederstadt et al.
GUT (2020)
Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes
Nicole Kiweler et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Characterization of a dualBET/HDACinhibitor for treatment of pancreatic ductal adenocarcinoma
Xin Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease
Linda Anna Michelle Kulka et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC
Viviane Ponath et al.
CANCERS (2020)
The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation
Melanie Dzulko et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression
Stephanie S. Kim et al.
THERANOSTICS (2020)
Regulation and pharmacological targeting of RAD51 in cancer
McKenzie K. Grundy et al.
NAR CANCER (2020)
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer
Andrew E. Shouksmith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine
Zay Yar Oo et al.
MOLECULAR ONCOLOGY (2019)
Validation of the γH2AX biomarker for genotoxicity assessment: a review
B. Kopp et al.
ARCHIVES OF TOXICOLOGY (2019)
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
Michael Orth et al.
RADIATION ONCOLOGY (2019)
Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy
Richard S. Laschanzky et al.
CANCERS (2019)
Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells
Dinesh Kumar et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2019)
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality
Shuichi Watanabe et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
p53 modifications: exquisite decorations of the powerful guardian
Yanqing Liu et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
Human Platelet Lysate as Validated Replacement for Animal Serum to Assess Chemosensitivity
Miriam Pons et al.
ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION (2019)
Trichostatin A alters cytoskeleton and energy metabolism of pancreatic adenocarcinoma cells: An in depth proteomic study
Elisa Dalla Pozza et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells
Miriam Pons et al.
ARCHIVES OF TOXICOLOGY (2018)
Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors
Sai-Wen Tang et al.
CLINICAL CANCER RESEARCH (2018)
Polyploidy in tissue homeostasis and regeneration
Jan Inge Ovrebo et al.
DEVELOPMENT (2018)
HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130
Anja Goeder et al.
NATURE COMMUNICATIONS (2018)
Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine
Mao-Hua Cai et al.
SCIENTIFIC REPORTS (2018)
Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
Sebastian Mueller et al.
NATURE (2018)
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
Emily Chan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
N. Stojanovic et al.
ONCOGENE (2017)
Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4-and MYC-dependent manner
Vivek Kumar Mishra et al.
NUCLEIC ACIDS RESEARCH (2017)
Interstrand Crosslink Repair as a Target for HDAC Inhibition
Teodora Nikolova et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage
Lukas Perkhofer et al.
CANCER RESEARCH (2017)
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells
Claudia Schaefer et al.
CELLULAR SIGNALLING (2017)
ATR inhibition rewires cellular signaling networks induced by replication stress
Sebastian A. Wagner et al.
PROTEOMICS (2016)
Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer
Emily Chan et al.
RADIOTHERAPY AND ONCOLOGY (2016)
HDAC3 mediates smoking-induced pancreatic cancer
Mouad Edderkaoui et al.
ONCOTARGET (2016)
Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia
Calum Leitch et al.
ONCOTARGET (2016)
Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-421,2
Sally E. Henderson et al.
NEOPLASIA (2016)
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
Pawel K. Mazur et al.
NATURE MEDICINE (2015)
Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition
Ronan Russell et al.
NATURE COMMUNICATIONS (2015)
A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer
Roland H. Stauber et al.
Oncotarget (2015)
The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro
Mei-Chuan Chen et al.
MOLECULAR PHARMACOLOGY (2015)
A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer
Nina Schoenhuber et al.
NATURE MEDICINE (2014)
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
Guido Finazzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Targeting apoptosis pathways in pancreatic cancer
Alexander Arlt et al.
CANCER LETTERS (2013)
A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance
Bingsen Zhou et al.
CANCER RESEARCH (2013)
ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA
Luis Ignacio Toledo et al.
CELL (2013)
Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients
Ariel Amaru Calzada et al.
EXPERIMENTAL HEMATOLOGY (2013)
HMGA2 Inhibits Apoptosis through Interaction with ATR-CHK1 Signaling Complex in Human Cancer Cells
Suchitra Natarajan et al.
NEOPLASIA (2013)
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer
Dmitriy I. Dovzhanskiy et al.
BMC CANCER (2012)
NF kappa B/p53 crosstalk-a promising new therapeutic target
Guenter Schneider et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2011)
Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11
Katharina Schlacher et al.
CELL (2011)
Targeting histone deacetylases in pancreatic ductal adenocarcinoma
Guenter Schneider et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells
Susanne Schueler et al.
MOLECULAR CANCER (2010)
Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and Repair
Eva Petermann et al.
MOLECULAR CELL (2010)
Cross talk between stimulated NF-κB and the tumor suppressor p53
G. Schneider et al.
ONCOGENE (2010)
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease
James E. Bradner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
E-Cadherin Regulates Metastasis of Pancreatic Cancer In Vivo and Is Suppressed by a SNAIL/HDAC1/HDAC2 Repressor Complex
Johannes von Burstin et al.
GASTROENTEROLOGY (2009)
A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint
Rachel Beckerman et al.
GENES & DEVELOPMENT (2009)
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA
P. Fritsche et al.
GUT (2009)
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion
Sarah E. Golding et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis
O. H. Kraemer et al.
ONCOGENE (2008)
Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells
O. Ammerpohl et al.
BRITISH JOURNAL OF CANCER (2007)
Replication in hydroxyurea: It's a matter of time
Gina M. Alvino et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling
Thomas Stiff et al.
EMBO JOURNAL (2006)
Stalled replication induces p53 accumulation through distinct mechanisms from DNA damage checkpoint pathways
CC Ho et al.
CANCER RESEARCH (2006)
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia
G Bug et al.
CANCER (2005)
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
OH Krämer et al.
EMBO JOURNAL (2003)
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
EL Jackson et al.
GENES & DEVELOPMENT (2001)
p53 down-regulates CHK1 through p21 and the retinoblastoma protein
V Gottifredi et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
分享论文
